Business Description
TaiGen Biopharmaceuticals Holdings Ltd
ISIN : KYG866171005
Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.52 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.25 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 59.1 | |||||
| Beneish M-Score | -1.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 73.4 | |||||
| 3-Year EPS without NRI Growth Rate | 62.2 | |||||
| 3-Year Book Growth Rate | 36.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.73 | |||||
| 9-Day RSI | 43.47 | |||||
| 14-Day RSI | 47.06 | |||||
| 6-1 Month Momentum % | -8.22 | |||||
| 12-1 Month Momentum % | -5.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 20.34 | |||||
| Quick Ratio | 19.5 | |||||
| Cash Ratio | 19.01 | |||||
| Days Inventory | 983.94 | |||||
| Days Sales Outstanding | 25.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.23 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.02 | |||||
| Operating Margin % | -106.23 | |||||
| Net Margin % | 157.35 | |||||
| FCF Margin % | -134.79 | |||||
| ROE % | 22.34 | |||||
| ROA % | 20.17 | |||||
| ROIC % | -96.02 | |||||
| ROC (Joel Greenblatt) % | 218.64 | |||||
| ROCE % | 21.59 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 43.76 | |||||
| PE Ratio without NRI | 108.28 | |||||
| PS Ratio | 69.56 | |||||
| PB Ratio | 8.83 | |||||
| Price-to-Tangible-Book | 8.94 | |||||
| EV-to-EBIT | 38.61 | |||||
| EV-to-EBITDA | 34.89 | |||||
| EV-to-Revenue | 62.23 | |||||
| EV-to-FCF | -47.6 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Price-to-Graham-Number | 6.55 | |||||
| Price-to-Net-Current-Asset-Value | 9.66 | |||||
| Price-to-Net-Cash | 10.43 | |||||
| Earnings Yield (Greenblatt) % | 2.59 | |||||
| FCF Yield % | -1.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TaiGen Biopharmaceuticals Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 149.454 | ||
| EPS (TTM) (NT$) | 0.329 | ||
| Beta | 0.46 | ||
| Volatility % | 13.13 | ||
| 14-Day RSI | 47.06 | ||
| 14-Day ATR (NT$) | 0.288603 | ||
| 20-Day SMA (NT$) | 14.5275 | ||
| 12-1 Month Momentum % | -5.42 | ||
| 52-Week Range (NT$) | 13.05 - 17.25 | ||
| Shares Outstanding (Mil) | 717.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TaiGen Biopharmaceuticals Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TaiGen Biopharmaceuticals Holdings Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
TaiGen Biopharmaceuticals Holdings Ltd Frequently Asked Questions
What is TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157)'s stock price today?
The current price of ROCO:4157 is NT$14.40. The 52 week high of ROCO:4157 is NT$17.25 and 52 week low is NT$13.05.
When is next earnings date of TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157)?
The next earnings date of TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157) is .
Does TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157) pay dividends? If so, how much?
TaiGen Biopharmaceuticals Holdings Ltd(ROCO:4157) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers